All News

Found 2,621 articles

• Ten63 Therapeutics Raises $15.9 Million in Oversubscribed Series A Financing to Drug the Undruggables by Combining the Power of AI and Physics-based Models

  5/2/2023

  Ten63 Therapeutics, a company combining generative AI and physics-based models to develop first- and best-in-class therapeutics, today announced the closing of an oversubscribed $15.9 million Series A financing led by new investor Hatteras Venture Partners.

• Envision Pharma Group Appoints Industry Leader Tino Quintero as General Manager/VP of Market Access & Customer Insights

  5/1/2023

  Envision Pharma Group (Envision) has appointed Tino Quintero to the role of General Manager/VP of Market Access & Customer Insights.

• Vertex Reports First Quarter 2023 Financial Results

  5/1/2023

  Vertex Pharmaceuticals Incorporated reported consolidated financial results for the first quarter ended March 31, 2023 and reiterated full year 2023 financial guidance.

• Dennis Huang of Ultragenyx Named to MassBio’s Board of Directors

  4/28/2023

  Ultragenyx Pharmaceutical Inc. announced Dennis Huang, chief technical operations officer and executive vice president, gene therapy, has been named to the Massachusetts Biotechnology Council board of directors.

• ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results

  4/28/2023

  ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023.

• Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations

  4/26/2023

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis (CF) ages 2 through 5 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive to TRIKAFTA® based on in vitro data.

• 

  Bluebird Submits BLA for Sickle-Cell Disease Gene Therapy

  4/25/2023

  The regulatory filing puts the company alongside Vertex and CRISPR, which also await FDA approval for their SCD gene therapy.

• Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9

  4/25/2023

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Bank of America Securities 2023 Health Care Conference on Tuesday, May 9, 2023 at 9:20 a.m. PT/12:20 p.m. ET.

• Cardurion Pharmaceuticals Further Bolsters Leadership Team with Appointment of Stephen Migausky as General Counsel

  4/19/2023

  Cardurion Pharmaceuticals, Inc. today announced the appointment of Stephen Migausky as Senior Vice President and General Counsel.

• CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference

  4/13/2023

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at the 22nd Annual Needham Healthcare Conference being held virtually from April 17th- 20th, 2023.

• TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics

  4/13/2023

  TORL BioTherapeutics LLC (TORL), a biopharmaceutical company focused on developing new biologics for cancer treatment, announced today its public launch and the closing of a $158 million Series B financing.

• 

  Gene Editing Therapeutics Could Hit the Market in 2023

  4/10/2023

  Currently, there are no gene editing–based treatments on the market, but the technology continues its march toward potential FDA approval, with several products in mid- and late-stage trials.

• Vertex Announces Health Canada Market Authorization for ORKAMBI& (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 1 to 2 Years

  4/10/2023

  Vertex Pharmaceuticals ( Canada ) Incorporated  (Nasdaq: VRTX) today announced that Health Canada, as a partner of the Access Consortium, has granted Marketing Authorization for the expanded use of PrORKAMBI® (lumacaftor/ivacaftor) for the treatment of cystic fibrosis (CF) in children ages 1 to <2 years who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

• Vertex to Announce First Quarter 2023 Financial Results on May 1

  4/10/2023

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2023 financial results on Monday, May 1, 2023 after the financial markets close.

• Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization

  4/10/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointments of two senior leaders to its research and development organization, Douglas E. Williams, Ph.D., as President of Research and Development, and Gary Meininger, M.D., as Chief Medical Officer.

• 

  Intellia Seeks to Broaden Gene Editing’s Potential with Full-Spectrum Approach

  4/4/2023

  With several recent milestones, Intellia Therapeutics is setting a solid foundation for gene editing in rare diseases with an eye toward broader patient populations.
• 

  Vertex and CRISPR Advance First-In-Kind Therapeutic for SCD

  4/3/2023

  In a potential leap forward for sickle cell disease, Vertex moved closer to launching its one-time treatment for sickle cell disease and transfusion-dependent beta-thalassemia.

• Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

  4/3/2023

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the rolling Biologics License Applications (BLAs) to the U.S. Food and Drug Administration (FDA) for the investigational treatment exagamglogene autotemcel (exa-cel) for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

• CRISPR Therapeutics Announces Departure of Board Member

  3/29/2023

  CRISPR Therapeutics today announced that Brad Bolzon, Ph.D., Chairman and Managing Director of Versant Ventures, is stepping down from the Board of Directors after nearly a decade of service.

• Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors

  3/28/2023

  Virpax ® Pharmaceuticals, Inc. announced today that the Company has appointed Barbara A. Ruskin, Ph.D, J.D. to its Board of Directors, increasing the size of the Board to nine members.